Profit figures
60 Degrees Pharmaceuticals posted a net profit of $2.1 million for the second quarter of 2025. Analysts on average had been forecasting a profit of roughly $1.5 million for the period, so the result came in about $0.6 million (≈40 %) above consensus expectations.
How the results compare to expectations and what it means for the market
The beat was driven by a higher‑margin cash‑pay sales mix that offset the revenue shortfall caused by a temporary supply‑chain constraint. The $2.1 million profit, together with the $1.97 million cash balance that now extends the company’s cash runway to March 2026, signals that the operating model can still generate positive earnings even when top‑line growth is modest. Analysts had been relatively cautious, pricing in the supply issue and expecting a modest loss or breakeven; the surprise upside therefore cleared a short‑covering rally and gave the stock a technical upside—the price has already broken above the Q2‑25 high‑volume node on the daily chart and is testing the 20‑day moving‑average resistance around $4.20.
Actionable insight
Given the profit beat, the cash‑runway extension, and the upside momentum on the chart, the trade‑set‑up leans toward a short‑term bullish bias. A prudent play would be to go long on any pull‑back to the 20‑day moving average (≈$4.20) with a stop just below the recent low around $3.90. If the stock can hold that level, the next upside target is the next resistance at $4.60–$4.70, where the 4‑week high and a prior swing‑high lie. Conversely, a breach below $3.90 could signal that the profit beat was already priced in and that the supply‑chain headwinds may still weigh on the stock, prompting a defensive exit.